Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
fda
genentech
3
×
life sciences
national blog main
national top stories
roche
boston
boston blog main
boston top stories
clinical trials
deals
san francisco blog main
san francisco top stories
avapritinib
billy dunn
biogen
blueprint medicines
cancer
cancer immunotherapy
center for medicare and medicaid services
companion diagnostic
cstone pharmaceuticals
daniel o'day
drug prices
drug pricing
eli lilly
europe top stories
european medicines agency
evrysdi
fisogatinib
flatiron health
foundation medicine
foundationone cdx
foundationone heme
gene therapy
hepatocellular carcinoma
investing
ionis pharmaceuticals
jeff albers
What
roche
3
×
drug
fda
medicine
acquire
agreed
approval
approved
atrophy
big
billion
blueprint
broad
cancer
candidate
confidence
currently
daily
didn’t
evrysdi
foundation
friday
gain
genentech
green
home
intended
lights
liquid
marketing
medicines
momentum
morning
muscle
muscular
new
oral
pact
panels
patients
Language
unset
Current search:
roche
×
genentech
×
@xconomy.com
3 years ago
FDA Green-Lights Roche Spinal Muscular Atrophy Drug, First Oral Therapy
@xconomy.com
3 years ago
Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact
@xconomy.com
5 years ago
In a Genentech Redux, Roche Pays $2.4B for Rest of Foundation Medicine